405920.Kq
The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.
Business. The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.
The company maintains a market price of 2415.0 KRW per share, with a market capitalization of 30,990,229,095 KRW. Its price-to-earnings ratio is 364.58, significantly higher than the typical range for the industry, indicating a high valuation relative to earnings. The price-to-book ratio is 0.48, suggesting that the company is trading at a discount to its book value. The enterprise value to EBITDA ratio is 58.89, and the enterprise value to revenue ratio is 0.75, both of which are key metrics for assessing valuation in the retail sector.
Profitability metrics show a return on equity of 0.0013 and a return on assets of 0.0007, both of which are below the industry median, indicating weak returns relative to equity and asset base. The company's operating income is 1,053,736,940 KRW, with a gross profit of 36,227,240,090 KRW, but the net income is only 85,003,410 KRW, reflecting high operating and non-operating expenses. The company's debt-to-equity ratio is 0.56, which is relatively moderate, but the current ratio of 1.57 suggests that the company has sufficient short-term assets to cover its short-term liabilities.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk of revenue volatility due to regional economic or regulatory changes. The company's capital structure includes 36,318,449,440 KRW in long-term debt and 5,257,181,350 KRW in cash and equivalents, resulting in a net cash position that is negative after subtracting total debt.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The capital expenditure of -4,084,239,150 KRW indicates a reduction in investment in physical assets, which may signal a strategic shift or financial constraints. The free cash flow is negative at -468,598,100 KRW, suggesting that the company is not generating enough cash from operations to cover its capital expenditures.
The company faces moderate liquidity risk, as indicated by the risk assessment, and low dilution risk. However, the negative net cash position after subtracting total debt is a key flag that could impact the company's ability to meet short-term obligations. The risk assessment also highlights the need for close monitoring of the company's liquidity position.
Recent events, including the latest financial filing, show a decline in profitability and a reduction in capital expenditures. The company's operating cash flow is 6,865,617,500 KRW, which is positive but not sufficient to cover the capital expenditures. The company's financial health is further complicated by the high price-to-earnings ratio and low return on equity, which may deter investors seeking strong returns.
- The company is trading at a high price-to-earnings ratio, indicating a premium valuation relative to earnings.
- The company's return on equity and return on assets are below the industry median, suggesting weak profitability.
- The company has a moderate debt-to-equity ratio but a negative net cash position after subtracting total debt.
- The company's free cash flow is negative, indicating that it is not generating enough cash from operations to cover its capital expenditures.
- The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 405920.KQ Market data — financials · 2026-05-26